Biogen Inc. (BIIB) vs Organon & Co. (OGN)
Biogen Inc. and Organon & Co. are both Drug Manufacturers General companies. Biogen Inc. is the larger, with a market value of $33.5B against $3.6B — 9.3× the size. Organon & Co. trades at the lower P/E: 17.4× against 40.1×. Biogen Inc. grew revenue faster over the last twelve months: 0.31% against −2.45%. Biogen Inc. has the higher net margin (8.32% vs 3.41%) and the lower return on invested capital (3.11% vs 6.11%). Across the 22 metrics below, Organon & Co. leads on 12 and Biogen Inc. on 10.
Valuation
Profitability
| Metric | BIIB | OGN | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 73.99% | 52.68% | 72.77% |
| Operating margin | 12.35% | 13.45% | 18.90% |
| Net margin | 8.32% | 3.41% | 8.27% |
| Free cash flow margin | 25.33% | 7.57% | 17.25% |
| Return on equity | 4.58% | 24.04% | 6.97% |
| Return on assets | 2.76% | 1.57% | 2.76% |
| Return on invested capital | 3.11% | 6.11% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack